Stem cell mobilization in HIV seropositive patients with lymphoma

Haematologica

Volumn 98, Issue 11, 2013, Pages 1762-1768

  Re, Alessandro ^a   Cattaneo, Chiara ^a   Skert, Cristina ^b   Balsalobre, Pascual ^c   Michieli, Mariagrazia ^d   Bower, Mark ^e   Ferreri, Andrés J M ^f   Hentrich, Marcus ^g   Ribera, José M ^h   Allione, Bernardino ⁱ   Schommers, Philipp ^j   Montoto, Silvia ^k   Almici, Camillo ^l   Ferremi, Pierino ^l   Mazzucato, Mario ^d   Gattillo, Salvatore ^f   Casari, Salvatore ^m   Spina, Michele ^d   Diez Martin, José L ^c   Tirelli, Umberto ^d   Rossi, Giuseppe ^a   more..

^a Hematology Department   (Italy)

^b UNIVERSITY OF BRESCIA   (Italy)

^c HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

^d CENTRO DI RIFERIMENTO ONCOLOGICO   (Italy)

^e CHELSEA AND WESTMINSTER HOSPITAL   (United Kingdom)

^f SAN RAFFAELE HOSPITAL   (Italy)

^g Harlaching Hospital   (Germany)

^h HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

ⁱ C Arrigo Children's Hospital   (Italy)

^j UNIVERSITY OF COLOGNE   (Germany)

^k QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^l Spedali Civili   (Italy)

^m Infectious Diseases Department   (Italy)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CD34 ANTIGEN; CYCLOPHOSPHAMIDE; GRANULOCYTE COLONY STIMULATING FACTOR; PLERIXAFOR;

ADULT; AGED; ARTICLE; BONE MARROW DISEASE; CD4 LYMPHOCYTE COUNT; DISEASE ASSOCIATION; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LEUKOCYTE COUNT; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; PREDICTION; PROGNOSIS; RETROSPECTIVE STUDY; STEM CELL MOBILIZATION; THROMBOCYTE COUNT; TREATMENT FAILURE;

ADULT; AGED; FEMALE; HEMATOPOIETIC STEM CELL MOBILIZATION; HIV SEROPOSITIVITY; HODGKIN DISEASE; HUMANS; LYMPHOMA, NON-HODGKIN; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; YOUNG ADULT;

EID: 84887001186     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2013.089052     Document Type: Article

References (42)

1. Schmitz N, Buske C, Gisselbrecht C. Autologous stem cell transplantation in lymphoma. Semin Hematol. 2007; 44(4): 234-45.
2. Schmitz N, Linch DC, Dreger P, Goldstone AH, Boogaerts MA, Ferrant A, et al. Randomised trial of filgrastim-mobilised peripheral blood progenitor cell transplantation versus autologous bone-marrow transplantation in lymphoma patients. Lancet. 1996; 347(8998): 353-7.
3. Siena S, Schiavo R, Pedrazzoli P, Carlo-Stella C. Therapeutic relevance of CD34 cell dose in blood cell transplantationfor cancer therapy. J Clin Oncol. 2000; 18(6): 1360-77.
4. Solà C, Maroto P, Salazar R, Mesía R, Mendoza L, Brunet J, et al. Bone Marrow Transplantation: Prognostic Factors of Peripheral Blood Stem Cell Mobilization with Cyclophosphamide and Filgrastim (rmetHuG-CSF): The CD34+ Cell Dose Positively Affects the Time to Hematopoietic Recovery and Supportive Requirements after High-Dose Chemotherapy. Hematology. 1999; 4(3): 195-209.
5. Bender JG, To LB, Williams S, Schwartzberg LS. Defining a therapeutic dose of peripheral blood stem cells. J Hematother. 1992; 1(4): 329-41.
6. Gandhi MK, Jestice K, Scott MA, Bloxham D, Bass G, Marcus RE. The minimum CD34 threshold depends on prior chemotherapy in autologous peripheral blood stem cell recipients. Bone Marrow Transplant. 1999; 23(1): 9-13.
7. To LB, Haylock DN, Simmons PJ, Juttner CA. The biology and clinical uses of blood stem cells. Blood. 1997; 89(7): 2233-58.
8. Pusic I, Jiang SY, Landua S, Uy GL, Rettig MP, Cashen AF, et al. Impact of mobilization and remobilization strategies on achieving sufficient stem cell yields for autologous transplantation. Biol Blood Marrow Transplant. 2008; 14(9): 1045-56.
9. Gertz MA. Current status of stem cell mobilization. Br J Haematol. 2010; 150(6): 647-62.
10. To LB, Levesque JP, Herbert KE. How I treat patients who mobilize hematopoietic stem cells poorly. Blood. 2011; 118(17): 4530-40.
11. Pusic I, DiPersio JF. The use of growth factors in hematopoietic stem cell transplantation. Curr Pharm Des. 2008; 14(20): 1950-61.
12. Levine AM. Acquired Immunodeficiency syndrome-related lymphoma: clinical aspects. Semin Oncol. 2000; 27(4): 442-53.
13. Palella FJ, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Satten GA, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med. 1998; 338(13): 853-60.
14. Gabarre J, Azar N, Autran B, Katlama C, Leblonde V. High-dose therapy and autologous haematopoietic stem-cell transplantation for HIV-1-associated lymphoma. The Lancet. 2000; 355(9209): 1071-2.
15. Re A, Cattaneo C, Michieli M, Casari S, Spina M, Ruolo M, et al. High-dose therapy and autologous peripheral-blood stem cell transplantation as salvage treatment for HIV associated lymphoma in patients receiving highly active antiretroviral therapy. J Clin Oncol. 2003; 21(23): 4423-7.
16. Krishnan A, Molina A, Zaia J, Smith D, Vasquez D, Kogut N, et al. Durable remissions with autologous stem cell transplantation for high-risk HIV-associated lymphomas. Blood. 2005; 105(2): 874-8.
17. Serrano D, Carrion R, Balsalobre P, Miralles P, Berenguer J, Buno I, et al. HIV associated lymphoma successfully treated with peripheral blood stem cell transplantation. Exp Hematol. 2005; 33(4): 487-94.
18. Diez-Martín JL, Balsalobre P, Re A, Michieli M, Ribera JM, Canals C, et al; European Group for Blood and Marrow Transplantation Lymphoma Working Party. Comparable survival between HIV+ and HIV-non-Hodgkin and Hodgkin lymphoma patients undergoing autologous peripheral blood stem cell transplantation. Blood. 2009; 113(23): 6011-4.
19. Sloand EM, Young NS, Sato T, Kumar P, Kim S, Weichold FF, et al. Secondary colony formation after long-term bone marrow culture using peripheral blood and bone marrow of HIV-infected patients. AIDS. 1997; 11(13): 1547-53.
20. Zauli G, Capitani S. HIV-1-related mechanisms of suppression of CD34+ hematopoietic progenitors. Pathobiology. 1996; 64(1): 53-8.
21. Schooley RT, Mladenovic J, Sevin A, Chiu S, Miles SA, Pomerantz RJ, et al. Reduced mobilization of CD34+ stem cells in advanced human immunodeficiency virus type 1 disease. J Infect Dis. 2000; 181(1): 148-57.
22. Baillou C, Simon A, Leclercq V, Azar N, Rosenzwajg M, Herson S, et al. Highly active antiretroviral therapy corrects hematopoiesis in HIV-1 infected patients: interest for peripheral blood stem cellbased gene therapy. AIDS. 2003; 17(4): 563-74.
23. Micallef IN, Apostolidis J, Rohatiner AZ, Wiggins C, Crawley CR, Foran JM, et al. Factors which predict unsuccessful mobilisation of peripheral blood progenitor cells following G-CSF alone in patients with non-Hodgkin's lymphoma. Hematol J. 2000; 1(6): 367-73.
24. Hosing C, Saliba RM, Ahlawat S, Körbling M, Kebriaei P, Alousi A, et al. Poor hematopoietic stem cell mobilizers: a single institution study of incidence and risk factors in patients with recurrent or relapsed lymphoma. Am J Hematol. 2009; 84(6): 335-7.
25. Wuchter P, Ran D, Bruckner T, Schmitt T, Witzens-Harig M, Neben K, et al. Poor mobilization of hematopoietic stem cellsdefinitions, incidence, risk factors, and impact on outcome of autologous transplantation. Biol Blood Marrow Transplant. 2010; 16(4): 490-9.
26. Sancho JM, Morgades M, Grifols JR, Juncà J, Guardia R, Vives S, et al. Predictive factors for poor peripheral blood stem cell mobilization and peak CD34(+) cell count to guide pre-emptive or immediate rescue mobilization. Cytotherapy. 2012; 14(7): 823-9.
27. Walker RE, Parker RI, Kovacs JA, Masur H, Lane HC, Carleton S, et al. Anemia and erythropoiesis in patients with the acquired immunodeficiency syndrome (AIDS) and Kaposi sarcoma treated with zidovudine. Ann Intern Med. 1988; 108(3): 372-6.
28. Neal TF, Holland HK, Baum CM, Villinger F, Ansari AA, Saral R, et al. CD34+ progenitor cells from asymptomatic patients are not a major reservoir for human immunodeficiency virus-1. Blood. 1995; 86(5): 1749-56.
29. Sloand EM, Maciejewski J, Kumar P, Kim S, Chaudhuri A, Young Neal. Protease inhibitors stimulate hematopoiesis and decrease apoptosis and ICE expression in CD34+ cells. Blood. 2000; 96(8): 2735-9.
30. Mounier N, Spina M, Gabarre J, Raphael M, Rizzardini G, Golfier JB, et al. AIDS-related non-Hodgkin lymphoma: final analysis of 485 patients treated with risk-adapted intensive chemotherapy. Blood. 2006; 107 (10): 3832-40.
31. Rossi G, Donisi A, Casari S, Re A, Cadeo G, Carosi G. Cancer. The International Prognostic Index can be used as a guide to treatment decisions regarding patients with human immunodeficiency virus-related systemic non-Hodgkin lymphoma. Cancer. 1999; 86(11): 2391-7.
32. Tedeschi R, Bortolin MT, Bidoli E, Zanussi S, Pratesi C, Vaccher E, et al. Assessment of immunovirological features in HIV related non-Hodgkin lymphoma patients and their impact on outcome. J Clin Virol. 2012; 53(4): 297-301.
33. Re A, Michieli M, Casari S, Allione B, Cattaneo C, Rupolo M, et al. High dose therapy and autologous peripheral blood stem cell transplantation as salvage treatment for HIV-associated lymphoma: long term results of the GICAT study with analysis of prognostic factors. Blood. 2009; 114(7): 1306-13.
34. Narayanasami U, Kanteti R, Morelli J, Klekar A, Al-Olama A, Keating C, et al. Randomized trial of filgrastim versus chemotherapy and filgrastim mobilization of hematopoietic progenitor cells for rescue in autologous transplantation. Blood. 2001; 98(7): 2059-64.
35. Meldgaard KL, Jensen L, Gaarsdal E, Nikolaisen K, Johnsen HE. A comparative study of sequential priming and mobilisation of progenitor cells with rhG-CSF alone and high-dose cyclophosphamide plus rhG-CSF. Bone Marrow Transplant. 2000; 26(7): 717-22.
36. Schulman KA, Birch R, Zhen B, Pania N, Weaver CH. Effect of CD34(+) cell dose on resource utilization in patients after highdose chemotherapy with peripheral-blood stem-cell support. J Clin Oncol. 1999; 17(4): 1227-33.
37. Weaver CH, Hazelton B, Birch, R, Palmer P, Allen C, Schwartzberg L, West W. An analysis of engraftment kinetics as a function of the CD34 content of peripheral blood progenitor cell collections in 692 patients after the administration of myeloablative chemotherapy. Blood. 1995; 86(10): 3961-9.
38. Ahn JS, Park S, Im SA, Yoon SS, Lee JS, Kim BK, et al. High-dose versus low-dose cyclophosphamide in combination with GCSF for peripheral blood progenitor cell mobilization. Korean. J Inter Med. 2005; 20(3): 224-31.
39. Tarella C, Zallio F, Caracciolo D, Cherasco C, Bondesan P, Gavarotti P, et al. Hematopoietic progenitor cell mobilization and harvest following an intensive chemotherapy debulking in indolent lymphoma patients. Stem Cells. 1999; 17(1): 55-61.
40. Olivieri A, Marchetti M, Lemoli R, Tarella C, Icone A, Lanza F, et al. Proposed definition of "poor mobilizer" in lymphoma and multiple myeloma: an analytic hierarchy process by ad hoc working group Gruppo Italiano Trapianto di Midollo Osseo. Bone Marrow Transplant. 2012; 47(3): 342-51.
41. DiPersio JF, Micallef IN, Stiff PJ, Bolwell BJ, Maziarz RT, Jacobsen E, et al. Phase III prospective randomized double-blind placebo-controlled trial of plerixafor plus granulocyte colony-stimulating compared with placebo plus granulocyte-colony-stimulating factor for autologous stem-cell mobilization and transplantation for patients with non-Hodgkin's lymphoma. J Clin Oncol. 2009; 27(28): 4767-73.
42. Hendrix CW, Collier AC, Lederman MM, Schols D, Pollard RB, Brown S, et al. Safety, pharmacokinetics, and antiviral activity of AMD3100, a selective CXCR4 receptor inhibitor, in HIV-1 infection. J Acquir Immune Defic Syndr. 2004; 37(2): 1253-62.